Treatment of Recurrent or Metastatic Uterine Adenosarcoma

Table 3

Treatment outcomes on recurrence with chemotherapy for recurrent or metastatic disease.

	Median survival	value	HR	95% CI
OS by pathology on recurrence
High-grade sarcomatous component only	17.6 mo
Similar to initial pathology	33.5 mo	0.035	0.47	0.23–0.96
1st line chemotherapy
OS
All patients	16.6 mo	—
Doxorubicin-based regimen	14.9 mo	—
Doxorubicin/ifosfamide	22.5 mo	ref
Other doxorubicin-based regimens	13.1 mo	0.18	2.18	0.69–6.88
Gemcitabine/docetaxel	24.9 mo	0.99	0.99	0.30–3.38
Platinum-based regimen	24.3 mo	0.49	0.60	0.14–2.53
PFS
All patients	7.0 mo	—
Doxorubicin-based regimen	8.5 mo	—
Doxorubicin/ifosfamide	15.4 mo	ref
Other doxorubicin-based regimens	6.5 mo	0.083	2.65	0.88–7.98
Gemcitabine/docetaxel	5.0 mo	0.27	1.87	0.62–5.63
Platinum-based regimen	5.7 mo	0.06	3.08	0.95–9.93
1st line chemotherapy additional treatments
OS
Surgery	21.6 mo
No surgery	11.9 mo	0.12	1.36	0.73–2.53
PFS
Surgery	12.0 mo
No surgery	3.6 mo	0.02	2.04	1.10–3.77
OS by hormonal therapy for patients with recurrence
Received hormonal therapy	34.7 mo
No hormonal therapy	17.6 mo	0.15	1.58	0.85–2.95
OS therapy for 1st recurrence	21.8 mo
Surgery	26.3 mo
No surgery	15.1 mo	0.54	1.21	0.66–2.24
Radiation	16.5 mo
No radiation	23.4 mo	0.58	0.83	0.42–1.63
Chemotherapy	18.6 mo
No chemotherapy	27.6 mo	0.58	0.85	0.47–1.53
Chemotherapy + surgery	23.4 mo
No chemotherapy + surgery	16.5 mo	0.97	1.01	0.55–1.85

OS, overall survival; PFS, progression-free survival; TTP, time to progression.